GILOTRIF Drug Patent Profile
✉ Email this page to a colleague
When do Gilotrif patents expire, and what generic alternatives are available?
Gilotrif is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and eighty-seven patent family members in forty-six countries.
The generic ingredient in GILOTRIF is afatinib dimaleate. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the afatinib dimaleate profile page.
DrugPatentWatch® Generic Entry Outlook for Gilotrif
Gilotrif was eligible for patent challenges on July 12, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 19, 2030. This may change due to patent challenges or generic licensing.
There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GILOTRIF?
- What are the global sales for GILOTRIF?
- What is Average Wholesale Price for GILOTRIF?
Summary for GILOTRIF
| International Patents: | 187 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 48 |
| Clinical Trials: | 17 |
| Patent Applications: | 476 |
| Drug Prices: | Drug price information for GILOTRIF |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GILOTRIF |
| What excipients (inactive ingredients) are in GILOTRIF? | GILOTRIF excipients list |
| DailyMed Link: | GILOTRIF at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for GILOTRIF
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for GILOTRIF
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National University Hospital, Singapore | Phase 2 |
| National Cancer Centre, Singapore | Phase 1 |
| Vanderbilt-Ingram Cancer Center | Phase 1 |
Pharmacology for GILOTRIF
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Protein Kinase Inhibitors |
Paragraph IV (Patent) Challenges for GILOTRIF
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| GILOTRIF | Tablets | afatinib dimaleate | 20 mg, 30 mg and 40 mg | 201292 | 7 | 2017-07-12 |
US Patents and Regulatory Information for GILOTRIF
GILOTRIF is protected by five US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of GILOTRIF is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting GILOTRIF
Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Process for preparing amino crotonyl compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Solid pharmaceutical formulations comprising BIBW 2992
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Quinazoline derivatives for the treatment of cancer diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Quinazoline derivatives and pharmaceutical compositions containing them
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting GILOTRIF
FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷ Sign Up
REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1200.120, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-001 | Jul 12, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-002 | Jul 12, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-003 | Jul 12, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-001 | Jul 12, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-001 | Jul 12, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GILOTRIF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-001 | Jul 12, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-003 | Jul 12, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-002 | Jul 12, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for GILOTRIF
When does loss-of-exclusivity occur for GILOTRIF?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 2062
Patent: FORMULACIONES FARMACEUTICAS SOLIDAS QUE COMPRENDEN BIBW 2992
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09254574
Patent: Solid pharmaceutical formulations comprising BIBW 2992
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0913379
Patent: formulações farmacêuticas sólidas compreendendo bibw 2992
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 26472
Patent: FORMULATIONS PHARMACEUTIQUES SOLIDES COMPRENANT DU BIBW 2992 (SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 10001275
Patent: Metodo para producir un producto intermedio compactado de bibw 2992 ma2 que comprende una etapa de compactacion por rodillos de bibw 2992 ma2 u opcionalmente en una premezcla con 0-1,0% de lubricante en un mezclador de caida libre o de volteo y una etapa de tamizado; producto intermedio compactado; comprimido.
Estimated Expiration: ⤷ Sign Up
China
Patent: 2056589
Patent: Solid pharmaceutical formulations comprising BIBW 2992
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 80463
Patent: FORMULACIONES FARMACEUTICAS SOLIDAS QUE COMPRENDEN BIBW 2992
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0161061
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 17895
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 99971
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 10010650
Patent: FORMULACIONES FARMACÉUTICAS SÓLIDAS QUE COMPRENDEN BIBW 2992.
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 2168
Patent: СПОСОБ ПОЛУЧЕНИЯ УПЛОТНЕННОГО ПРОМЕЖУТОЧНОГО ПРОДУКТА ДИМАЛЕАТА BIBW 2992 И ТВЕРДЫЕ ТАБЛЕТКИ, ПОЛУЧЕННЫЕ ИЗ ТАКОГО ПРОДУКТА (METHOD FOR PRODUCTION OF COMPACTED INTERMEDIATE DIMALEATE BIBW 2992 AND SOLID TABLETS PREPARED FROM SUCH INTERMEDIATE)
Estimated Expiration: ⤷ Sign Up
Patent: 1001852
Patent: ТВЕРДЫЕ ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СОДЕРЖАЩИЕ BIBW 2992
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 99971
Patent: FORMULATIONS PHARMACEUTIQUES SOLIDES COMPRENANT DU BIBW 2992 (SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 52478
Patent: SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 29863
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 9054
Patent: שיטה לייצור חומר ביניים דחוס של 2992 bibw, חומר ביניים דחוס זה והרכבי רוקחות מוצקים המכילים חומר ביניים דחוס זה (Method of producing a compacted intermediate of bibw 2992, such compacted intermediate and solid pharmaceutical formulations comprising said compacted intermediate)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 32367
Estimated Expiration: ⤷ Sign Up
Patent: 11522011
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 1240
Patent: SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 10012939
Patent: FORMULACIONES FARMACEUTICAS SOLIDAS QUE COMPRENDEN BIBW 2992. (SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 478
Patent: ČVRSTE FARMACEUTSKE FORMULACIJE KOJE SADRŽE BIBW 2992 (SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 030
Patent: Formulations pharmaceutiques solides comprenant du bibw 2992
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 9568
Patent: Compacted formulations comprising 4-[(3-chloro-4-fluorophenyl)amino-6-{ [4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino} -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate (BIBW 2992 dimaleate)
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 100252
Patent: NUEVAS FORMULACIONES FARMACEUTICAS SOLIDAS QUE COMPRENDEN DIMALEATO DE 4-[(3-CLORO-4-FLUOROFENIL) AMINO]-6-{[4-(N,N-DIMETILAMINO)-1-OXO-2-BUTEN-1-IL] AMINO}-7-((S)-TETRAHIDROFURAN-3-ILOXI)-QUINAZOLINA
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 99971
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 99971
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 943
Patent: ČVRSTE FARMACEUTSKE FORMULACIJE KOJE SADRŽE BIBW 2992 (SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992)
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 99971
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1007805
Patent: SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1641517
Estimated Expiration: ⤷ Sign Up
Patent: 110025908
Patent: SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 88031
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 53203
Estimated Expiration: ⤷ Sign Up
Patent: 1000472
Patent: New solid pharmaceutical formulations comprising BIBW 2992
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 10000557
Patent: SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 2549
Patent: СПОСОБ ПОЛУЧЕНИЯ УПЛОТНЕННОГО ПРОМЕЖУТОЧНОГО ПРОДУКТА ДИМАЛЕАТА BIBW 2992, УПЛОТНЕННЫЙ ПРОМЕЖУТОЧНЫЙ ПРОДУКТ И ТВЕРДАЯ ПЕРОРАЛЬНАЯ ТАБЛЕТКА;СПОСІБ ОДЕРЖАННЯ УЩІЛЬНЕНОГО ПРОМІЖНОГО ПРОДУКТУ ДИМАЛЕАТУ BIBW 2992, УЩІЛЬНЕНИЙ ПРОМІЖНИЙ ПРОДУКТ ТА ТВЕРДА ПЕРОРАЛЬНА ТАБЛЕТКА (PROCESS FOR THE PREPARATION OF COMPACTED INTERMEDIATE COMPRISING BIBW 2992 DIMALEATE, COMPACTED INTERMEDIATE AND SOLID DOSAGE FORM)
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 867
Patent: NUEVAS FORMULACIONES FARMACÉUTICAS SÓLIDAS QUE COMPRENDEN BIBW 2992
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering GILOTRIF around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Estonia | 200300300 | ⤷ Sign Up | |
| Taiwan | I453203 | ⤷ Sign Up | |
| Bulgaria | 66139 | ⤷ Sign Up | |
| Estonia | 05244 | Kinasoliinderivaadid, neid hendeid sisaldavad ravimid, nende kasutamine ja meetod nende valmistamiseks | ⤷ Sign Up |
| Eurasian Patent Organization | 200300671 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for GILOTRIF
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1345910 | 2014C/009 | Belgium | ⤷ Sign Up | PRODUCT NAME: AFATINIB ET SES TAUTOMERES, SES STEREOISOMERES ET SES SELS PHYSIOLOGIQUEMENT ACCEPTABLES AVEC DES ACIDES OU BASES INORGANIQUES OU ORGANIQUES, EN PARTICULIER, AFATINIB SOUS FORME DE SEL DE MALEATE OU DE DIMALEATE; AUTHORISATION NUMBER AND DATE: EU/1/13/879 20130927 |
| 1345910 | SPC/GB14/015 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: AFATINIB, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, IN PARTICULAR A SALT WITH MALEIC ACID; REGISTERED: UK EU/1/13/879/001 20130927; UK EU/1/13/879/002 20130927; UK EU/1/13/879/003 20130927; UK EU/1/13/879/004 20130927; UK EU/1/13/879/005 20130927; UK EU/1/13/879/006 20130927; UK EU/1/13/879/007 20130927; UK EU/1/13/879/008 20130927; UK EU/1/13/879/009 20130927; UK EU/1/13/879/010 20130927; UK EU/1/13/879/011 20130927; UK EU/1/13/879/012 20130927 |
| 1345910 | PA2014005 | Lithuania | ⤷ Sign Up | PRODUCT NAME: AFATINIBUM; REGISTRATION NO/DATE: EU/1/13/879/001-EU/1/13/879/012 20130925 |
| 1345910 | C01345910/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: AFATINIB; REGISTRATION NO/DATE: SWISSMEDIC 63042 17.01.2014 |
| 1345910 | PA2014005,C1345910 | Lithuania | ⤷ Sign Up | PRODUCT NAME: AFATINIBUM; REGISTRATION NO/DATE: EU/1/13/879/001-EU/1/13/879/012 20130925 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
